Market Closed -
Japan Exchange
02:00:00 2024-05-10 am EDT
5-day change
1st Jan Change
2,777
JPY
+1.61%
-1.03%
+18.07%
Mar. 25
Towa Pharmaceutical Completes Payment for Director Stock Compensation
MT
Mar. 07
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors
CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd.
Protosera, Inc. announced that it has signed a subscription agreement for the private placement of 40,000 shares through third-party allotment on March 24, 2021. The transaction will include participation from new investor Towa Pharmaceutical Co., Ltd. (TSE:4553) for 77.1% stake in the company. The transaction is subject to the approval from the company’s shareholders at the Extraordinary General Meeting scheduled to be held on March 30, 2021. The transaction has been approved by the board of directors of Towa Pharmaceutical Co., Ltd. (TSE:4553). The transaction is expected to close on March 31, 2021.
Towa Pharmaceutical Completes Payment for Director Stock Compensation
Mar. 25
MT
VIE STYLE, Inc. announced that it has received ¥305 million in funding from Otsuka Holdings Co., Ltd., KAYAC Inc., Taisho Pharmaceutical Holdings Co., Ltd., Towa Pharmaceutical Co., Ltd., PE&HR Co., Ltd., Murata Manufacturing Co., Ltd. and other investors
Mar. 06
CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023
23-05-15
CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG).
22-03-06
CI
Towa Pharmaceutical Co., Ltd. agreed to acquire Sunsho Pharmaceutical Co., Ltd. from Carlyle Japan Partners III, a fund managed by The Carlyle Group Inc. (NasdaqGS:CG) for ¥47.7 billion.
21-12-16
CI
Protosera, Inc. announced that it expects to receive funding from Towa Pharmaceutical Co., Ltd.
21-03-23
CI
Luye Pharma : Strikes Licensing Deal with Japan's Towa Pharma for Alzheimer's Disease Drug
21-02-18
MT
Luye Pharma Switzerland AG and Towa Pharmaceutical Co., Ltd. Enters Strategic Collaboration to Develop and Commercialize Rivastigmine Multi-Day Transdermal Patch in Japan
21-02-17
CI
Towa Pharmaceutical Co., Ltd. completed the acquisition of Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.
20-01-30
CI
Innophys Co., Ltd. announced that it has received ¥3.53 billion in funding from a group of investors
19-12-24
CI
Towa Pharmaceutical Co., Ltd. signed an agreement to acquire Pensa Investments S.L. from Esteve Pharmaceuticals, S.A.
19-12-22
CI
Innophys Co., Ltd. announced that it expects to receive funding from Hi-Lex Corporation
19-11-08
CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2016; Provides Earnings Guidance for the Full Year Ending March 2016; Revises Capital Expenditure Guidance for the Year Endings March 2017 and 2018
16-05-13
CI
Towa Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter Ended December 2015; Reaffirms Earnings Guidance for the Full Year Ending March 2016
16-02-07
CI
Certain common shares of Towa Pharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 19-JAN-2016.
16-01-18
CI
Tranche Update on Towa Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on July 7, 2015.
15-09-10
CI
Towa Pharmaceutical Co., Ltd.'s Equity Buyback announced on July 7, 2015, has expired with repurchase of 592,000 shares, representing 3.48% for ¥4,999.53 million.
15-09-09
CI
Towa Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
15-07-06
CI
Towa Pharmaceutical Co., Ltd. announces an Equity Buyback for 700,000 shares, representing 4.12% for ¥5,000 million.
15-07-06
CI
Towa Pharmaceutical Co., Ltd. Announces Earnings Results for the Second Quarter of Fiscal Year 2015; Provides Earnings Guidance for the Full Year Ending March 2015
14-11-09
CI
Towa Pharmaceutical Co. Ltd. Reports Earnings Results for the Third Quarter of the Year Ending March 2014; Revised Earnings Guidance for Year Ending March, 2014
14-02-09
CI
Towa Pharmaceutical Co. Ltd. Announces Consolidated and Non-Consolidated Earnings Results for the First Quarter Ended June 30, 2012; Provides Earnings Guidance for the Second Quarter of Fiscal 2013
12-08-09
CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non Consolidated Earnings Results for the Year Ended March 2012; Revised Earnings Guidance for the Year Ending March 2013
12-05-13
CI
Towa Pharmaceutical Co. Ltd. Reports Consolidated and Non-Consolidated Earnings Results for the Third Quarter of 2011; Reaffirms Earnings Guidance for the Year Ending March, 2012
12-02-12
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Towa Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceuticals. The main products are generic drugs, which are launched after the efficacy and safety of new drugs have been confirmed for a certain period of time. It is a drug with the same effect, usage and dosage. The Company is involved in the sale and outsourced manufacture of products and generic drugs. The Company is involved in the research and outsourced manufacture of active pharmaceutical ingredient and soft capsules. The Company is also involved in the planning, development, contract manufacturing of health foods, general foods, miscellaneous goods and others.
More about the company
Last Close Price
2,777
JPY
Average target price
3,690
JPY
Spread / Average Target
+32.88%
Consensus
1st Jan change
Capi.
+18.07% 877M +30.38% 684B +26.51% 568B -4.36% 361B +19.30% 329B +3.73% 284B +16.70% 240B +8.78% 208B -7.93% 200B +7.68% 166B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1